March 2015
SACF officially launches new research lab in El Monte, California.
July 2015
SACF links Taipei Medical University with Lixte Biotechnology Holdings Inc in signing Non Disclosure Agreement that aims to explore the effectiveness of anti-cancer compound LB-100 in hepatocellular carcinoma in Asian populations.
January 2016
SACF and California Cancer Institute work together in identifying and evaluating potential biomarkers related to cancer diagnosis, prognosis, and therapy.
July 2016
SACF announces new research focus in cytotoxicity studies, protein assays, and predictive simulation models to elucidate mechanisms of action and potential targets for cancer drug development.
August 2016
SACF completes 2016 Summer Student Research Internship Program. Motivated high school and college students with strong interests in research and health sciences participate in research and work activities under the supervision of staff scientists for two-month period.
January 2017
In conjunction with University of Oslo and Human Frontier Science Program, SACF pledges support for innovative, cutting edge research related to cancer medicine and open international collaborations in the spirit of science without borders.
June 2017
SACF publishes “Benefits and Harms of the Center for Medicare & Medicaid Services Ruling on Next Generation Sequencing” in JAMA Internal Medicine.
July 2017
SACF visits Zhongke Biopharma with Kedrion BioPharma Inc in efforts to foster international collaborations between pharma and global healthcare care industries.
August 2017
SACF 2017 Summer Student Research Internship Program.
September 2017
Yale School of Medicine and SACF collaborate on a clinical report involving novel mutation in Ribonucleotide Reductase Subunit M2 in relation to mitochondrial depletion syndrome.
August 2018
SACF 2018 Summer Student Research Internship Program.
September 2018
U.S. Patent Trademark Office (USPTO) grants SACF Provisional Patent for PYCR1 Candidate Inhibitors (File No.: S90140/US8125)
October 2018
SACF publishes “FDA Guidance for Next Generation Sequencing-based Testing: Balancing Regulation and Innovation in Precision Medicine” in Nature Genomic Medicine.
February 2019
SACF signs agreement with Bridgent Technologies Inc. to explore scientific medical cancer education program to Asia.
March 2019
U.S. FDA grants orphan drug designation to SACF’s Compound 056 for treatment of multiple myeloma.
April 2019
SACF relocates lab to Covina, CA and officially opens new headquarters.
July 2020
SACF signs Agreement with local biotech/pharma client to utilize Acceleration Lab for drug discovery research.
November 2020
SACF signs Agreement with biotech/pharma client to utilize Acceleration Lab for immunotherapy research.
December 2020
SACF announced the collaboration with Atomwise for IC50 for top hits/ Identify new scaffolds/ Identify useful tool/ control compounds/ Publication
January 2021
SACF collaborate with Atomwise in Drug Discovery Project identified potent RR inhibitors.
March 2021
Ribonucleotide Reductase: RRM2b Docking, Phe/Proton Coupled Electron Transfer, and N221S mutation. Scientific Reports Manuscript-“Critical Roles of Phenylalanine Chain and Asparagine in Human Ribonucleotide Reductase and Mitochondrial Depletion Syndrome”
July 2021
SACF Expansion Exploration: 668 Arrow Grand Circle 2nd floor: Total Space 7,000 SF.
September 2021
Two SACF articles published in 2020 were highlighted. Journal include: Trends in Biotechnology and Molecular Carcinogenesis.
October 2021
Activities with California Cancer Institute (CCI) to provide consultation services to OBI Pharma Taiwan/USA, and providing support service to Calgent Biotechnologies (TW) in Compound 056.
January 2022
SACF logo designed by Liam.
March 2022
SACF in the News: Atomwise and AIM Award Program/ 2022 Machine Learning is a Viable Alternative to High Throughput Screening: A 270 Target Case Study/ Contributing Research Sponsor/ 2022 Gordon Research Conferences-Personalized Medicine
April 2022
Project: Ribonucleotide Reductase: RRM2b Docking, Phe/Proton Coupled Electron Transfer, and N221S mutation, MDS.
May 2022
Manuscript submitted to Scientific Reports: Critical Roles of Phenylalanine Chain and Asparagine in Human Ribonucleotide Reductase and Mitochondrial Depletion Syndrome.
February 2023
SACF scientists/research staff worked on Title of manuscript “Structure Basis of the Human Ribonucleotide Reductase Small Subunit B Mutant N221S in Mitochondrial DNA Depletion Syndrome”
March 2023
SACF collaboration with Dr. Winston Ho of Applied Biocode to develop cancer mutation detection Kit.
November 2023
SACF published “Impact of N221S Missense Mutation in Human Ribonucleotide Reductase Small Subunit B on Mitochondrial DNA Depletion Syndrome” on Nature Scientific Reports.
March 2024
SACF published “AI is a viable alternative to high throughput screening: a 318-target study” on Nature Scientific Reports.